fbpx

Day

December 12, 2012
River Vision Development Corp. today announced the completion of a Series A financing, raising $17 million for the development of a novel protein therapy, RV 001, for the treatment of Graves' Orbitopathy (GO). GO is a condition afflicting a proportion of Graves' Disease patients, in which an autoimmune response is mounted against tissues behind the...

News

Experienced neuroscientist at the helm of The Brain Prize
30. June 2020
Eight promising young researchers receive Lundbeck Foundation Fellowships
16. June 2020
Denmark Gets Its First Master’s Degree Programme in Neuroscience
4. June 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge